• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Rules of the Game: Ponder Perrigo

The generic drugmaker shows new signs of life after months of struggle.
By KATE STALTER Feb 14, 2013 | 12:30 PM EST
Stocks quotes in this article: PRGO

Last week I wrote about S&P energy sector names whose earnings performances merited a glance. While energy remains the top-gaining S&P large-cap sector in this still-very-young year, health care is the runner-up, advancing 8.11% since Jan. 2.

For years, the medical sector has been home to dividend-yielding giants such as Pfizer (PFE) and Bristol-Myers Squibb (BMY), as well as growth leaders such as Alexion Pharmaceuticals (ALXN) and Intuitive Surgical (ISRG). In other words, if you're looking for large-cap names to round out a portfolio of individual stocks, you have plenty to analyze and choose from. I always begin by scanning for earnings and revenue growth on the fundamental side, augmented on the technical side by support above the 200-day moving average.

Generic drugmaker Perrigo (PRGO) shows new signs of life after several months of struggle. It was already trending lower when it gapped down on Nov. 7, following a first-quarter revenue miss. That's exactly the kind of intraday action that panics those with a trading mentality, rather than a longer-term investing mindset. I know, because I've been there and done that. I understand the thought process: Sell a stock like Perrigo when it gaps down or slashes key moving averages in heavy volume. It seems reasonable. You're keeping your capital and putting it to work in a trade that's going up.

That assumes, of course, that everything happens exactly the way the trader believes it will. The stock that gaps down will stay down, he will find a winner to put his money into, and sudden market swings (in either direction) will foul up the process. We know things don't work out perfectly like that. It took me many years to realize the futility of attempting such precise market timing.

So what does that mean for Perrigo? If you're not in the stock, this could be one to consider as a possible purchase. Of course, you have to take into account your other sector and market-cap exposure and your overall risk tolerance for individual stocks. If you own an individual stock, have a good reason for it -- not just because somebody mentioned it on TV or in an article like this one. The stock is up 11.2% so far in February, following better-than-expected second-quarter results earlier this month. This week, the company said it would acquire Rosemont Pharmaceuticals for about $283 million in cash. The U.K.-based company makes liquid medications.

The technical picture for Perrigo is fine right now, with the stock getting support above its 200-day average -- "Fine" as in not showing explosive price growth, but also not melting down.

On the fundamental side, earnings and revenue growth have been decelerating, but that does not necessarily signal the end of price appreciation, though it may mean slower growth. Additional acquisitions could help those numbers turn around in the next couple of years.

This year, analysts see the company earning $5.59 per share, up 12% over 2012. That's seen growing another 15% next year, to $6.42 per share.

I'm focusing on this stock today not because I'm head over heels about it. I am certainly not recommending a purchase, but it has some decent qualities, and is a good illustration of what to look for -- and of why it's not a great idea to abandon a stock just because it's trading below prior highs.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stalter had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Bearish Bets: 3 Stocks You Should Consider Shorting This Week

Bob Lang
Jul 3, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:01 PM EDT PAUL PRICE

    A Recent Director Buy in Children's Place (PLCE)

    Four of the most recent insider trades in Children...
  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login